Pharmaceutical News

RSS

Research supports COVID booster vaccines for those aged 60 and over

Israeli researchers conducted an important study to determine if the Pfizer-BioNTech BNT162b2 vaccine had become less effective in preventing infection.

13 Sep 2021

Pharmacotherapy for alcohol use disorder is underutilized in Sweden, finds study

Only a minority of Swedes with alcohol use disorders are prescribed alcohol medication, a situation that has remained largely unchanged in the country since the mid-2000.

13 Sep 2021

International reference pricing could yield considerable savings for prescription drugs in the U.S.

Linking the cost of prescription drugs in the United States to the prices paid in other high-income nations could have reduced American spending for the drugs by at least half in 2020, according to a new RAND Corporation study.

12 Sep 2021

Study shows how oncology practices changed after durvalumab approval for unresectable stage III NSCLC patients

A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for patients with unresectable Stage III non-small cell lung cancer.

12 Sep 2021

INCB, UNODC and WHO call on governments to facilitate access to controlled medicines in emergencies

Recognizing World Humanitarian Day 2021, the International Narcotics Control Board, the United Nations Office on Drugs and Crime and the World Health Organization once again call on governments to facilitate access to medicines containing controlled substances in emergency settings, including during pandemics and the increasing number of climate-related disasters.

10 Sep 2021

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Researchers in Australia have developed a coronavirus disease 2019 (COVID-9) vaccine that induced robust and long-lived humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in both young and aging mice.

8 Sep 2021

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

A new study successfully identifies a series of inhibitors that possesses pancoronavirus activity against SARS-CoV, SARS-CoV-2, and MERS-CoV.

7 Sep 2021

New analysis provides timely information on disparities in vaccine confidence among US adults

A peer-reviewed analysis of US national survey data of 75,000 adults shows, from early January to late March, a near "18 percentage point" increase of adults who have either had the COVID-19 vaccine jab or are willing to do have it.

7 Sep 2021

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

Scientists from the National Institutes of Health, USA, have recently demonstrated the immunogenicity and protective efficacy of two vesicular stomatitis virus (VSV)-based coronavirus disease 2019 (COVID-19) vaccines in hamsters.

6 Sep 2021

Efficacy of vaccines against the SARS-CoV-2 Delta variant

A new study uses statistical models to determine vaccine efficacy against the various SARS-CoV-2 variants and clinical endpoints for SARS-CoV-2 variants.

5 Sep 2021

UCD spin-out company secures €595k in seed funding to advance drug development

BioSimulytics (www.biosimulytics.ai), a University College Dublin (UCD) spin-out company, today announced that it has secured €595k in initial seed funding from a number of strategic angel investors and Enterprise Ireland.

2 Sep 2021

UC cosmetic scientist receives grant to explore skin permeation of chemical agents

A researcher at the University of Cincinnati is looking at ways to make products such as anti-aging and skin lightening creams, lotions, and gels more effective.

2 Sep 2021

An assessment of post-vaccination immune response to SARS-CoV-2 Delta in elderly and health care workers

A new cohort study comparing immune responses among vaccinated elderly persons and healthcare workers has been conducted.

2 Sep 2021

The tale of mRNA vaccines: Turning calamity into opportunity

In a review paper published in the journal Nature Reviews, researchers from Carnegie Mellon University and the University of Pennsylvania have described the underlying technologies for mRNA vaccines and their future prospects with improved delivery systems and applications in diseases beyond the ongoing COVID-19 pandemic.

31 Aug 2021

FDA grants seven years of marketing exclusivity for Octapharma’s Octagam 10%

Octapharma USA today announced the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded seven years of marketing exclusivity for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis (DM).

31 Aug 2021

New evidence provides strong support for the halt on prescribing hydroxychloroquine for COVID-19

In 2021, in the United States alone, there have been more than 560,000 prescriptions of hydroxychloroquine for the prevention, post-exposure and treatment of COVID-19.

31 Aug 2021

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

A new study shows that the highly effective mRNA Moderna vaccine designed against the original SARS-CoV-2 strain may lose some efficacy as new variants arise.

30 Aug 2021

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

A new study adds to the data on the optimum interval between the first and second doses of the adenovirus vectored COVID-19 vaccine.

30 Aug 2021

Next-gen COVID vaccine to make persistent neutralizing antibodies

Presently, there is a need to develop improved versions of COVID-19 vaccines that are effective against the SARS-CoV-2 variants of concern (VOC) and can confer long-term protection. Considering the need of the hour, scientists from the University of Sydney in Australia have generated a new COVID-19 vaccine CoVac-II and evaluated its effect against COVID-19 strains. The findings from this study are published on the bioRxiv* preprint server while awaiting peer review.

30 Aug 2021

Could soluble CD24 offer some hope against severe COVID-19?

A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.

26 Aug 2021

Pharmaceutical News

Research supports COVID booster vaccines for those aged 60 and over

Pharmacotherapy for alcohol use disorder is underutilized in Sweden, finds study

International reference pricing could yield considerable savings for prescription drugs in the U.S.

Study shows how oncology practices changed after durvalumab approval for unresectable stage III NSCLC patients

INCB, UNODC and WHO call on governments to facilitate access to controlled medicines in emergencies

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

New analysis provides timely information on disparities in vaccine confidence among US adults

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

Efficacy of vaccines against the SARS-CoV-2 Delta variant

UCD spin-out company secures €595k in seed funding to advance drug development

UC cosmetic scientist receives grant to explore skin permeation of chemical agents

An assessment of post-vaccination immune response to SARS-CoV-2 Delta in elderly and health care workers

The tale of mRNA vaccines: Turning calamity into opportunity

FDA grants seven years of marketing exclusivity for Octapharma’s Octagam 10%

New evidence provides strong support for the halt on prescribing hydroxychloroquine for COVID-19

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

Next-gen COVID vaccine to make persistent neutralizing antibodies

Could soluble CD24 offer some hope against severe COVID-19?

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News